[1] Patel NH, Vyas NS, Puri BK, et al. Positron emission tomography in schizophrenia: a new perspective. J Nucl Med, 2010, 51(4): 511-520.  doi: 10.2967/jnumed.109.066076
[2] Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry, 2003, 160(1): 13-23.  doi: 10.1176/appi.ajp.160.1.13
[3] Howes OD, Montgomery AJ, Asselin MC, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry, 2009, 66(1): 13-20.  doi: 10.1001/archgenpsychiatry.2008.514
[4] Elkashef AM, Doudet D, Bryant T, et al. 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Res, 2000, 100(1): 1-11.  doi: 10.1016/S0925-4927(00)00064-0
[5] Takahashi H, Higuchi M, Suhara T. The role of extrastriatal dopamine D2 receptors in schizophrenia. Biol Psychiatry, 2006, 59(10): 919-928.  doi: 10.1016/j.biopsych.2006.01.022
[6] Okubo Y, Suhara T, Suzuki K, et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature, 1997, 385(6617): 634-636.  doi: 10.1038/385634a0
[7] Yang YK, Yeh TL, Chiu NT, et al. Association between cognitive performance and striatal dopamine binding is higher in timing and motor tasks in patients with schizophrenia. Psychiatry Res, 2004, 131(3): 209-216.  doi: 10.1016/j.pscychresns.2003.07.002
[8] Kosaka J, Takahashi H, Ito H, et al. Decreased binding of [11C]NNC112 and[11C]SCH23390 in patients with chronic schizophrenia. Life Sci, 2010, 86(21-22): 814-818.  doi: 10.1016/j.lfs.2010.03.018
[9] Buchsbaum MS, Christian BT, Lehrer DS, et al. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res, 2006, 85(1-3): 232-244.  doi: 10.1016/j.schres.2006.03.042
[10] Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version Ⅲ-the final common pathway. Schizophr Bull, 2009, 35(3): 549-562.  doi: 10.1093/schbul/sbp006
[11] Dean B, Crossland N, Boer S, et al. Evidence for altered post-rec-eptor modulation of the serotonin 2a receptor in schizophrenia. Schizophr Res, 2008, 104(1-3): 185-197.  doi: 10.1016/j.schres.2008.06.011
[12] Alfimova MV, Lezheǐko TV, Golimbet VE, et al. Investigation of association of the brain-derived neurotrophic factor(BDNF)and a serotonin receptor 2A(5-HTR2A)genes with voluntary and involuntary attention in schizophrenia. Zh Nevrol Psikhiatr Im S S Korsakova, 2008, 108(4): 62-69.
[13] Ngan ET, Yatham LN, Ruth TJ, et al. Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: A PET study using [(18)F]setoperone. Am J Psychiatry, 2000, 157(6): 1016-1018.  doi: 10.1176/appi.ajp.157.6.1016
[14] Gefvert O, Lundberg T, Wieselgren IM, et al. D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol, 2001, 11(2): 105-110.  doi: 10.1016/S0924-977X(00)00133-4
[15] Mamo D, Kapur S, Shammi CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry, 2004, 161(5): 818-825.  doi: 10.1176/appi.ajp.161.5.818
[16] Fujimoto T, Takeuch K, Matsumoto T, et al. Abnormal glucose metabolism in the anterior cingulate cortex in patients with schizophrenia. Psychiatry Res, 2007, 154(1): 49-58.  doi: 10.1016/j.pscychresns.2006.04.002
[17] Kopecek M, Spaniel F, Novák T, et al. 18FDG PET in hallucinating and non-hallucinating patients. Neuro Endocrinol Lett, 2007, 28(1): 53-59.
[18] Harrison BJ, Yücel M, Shaw M, et al. Dysfunction of dorsolateral prefrontal cortex in antipsychotic-naïve schizophreniform psychosis. Psychiatry Res, 2006, 148(1): 23-31.  doi: 10.1016/j.pscychresns.2006.02.006
[19] Kim JJ, Park HJ, Jung YC, et al. Evaluative processing of ambivalent stimuli in patients with schizophrenia and depression: a [15O] H2O PET study. J Int Neuropsychol Soc, 2009, 15(6): 990-1001.  doi: 10.1017/S1355617709990403
[20] Brewer WJ, Yücel M, Harrison BJ, et al. Increased prefrontal cerebral blood flow in first-episode schizophrenia following treatment: longitudinal positron emission tomography study. Aust N Z J Psychiatry, 2007, 41(2): 129-135.  doi: 10.1080/00048670601109899
[21] Callicott JH, Mattay VS, Bertolino A, et al. Physiological characteristics of capacity constraints in working memory as revealed by functional MRI. Cereb Cortex, 1999, 9(1): 20-26.  doi: 10.1093/cercor/9.1.20
[22] Ko JH, Ptito A, Monchi O, et al. Increased dopamine release in the right anterior cingulate cortex during the performance of a sorting task: a [11C]FLB 457 PET study. Neuroimage, 2009, 46(2): 516-521.  doi: 10.1016/j.neuroimage.2009.02.031
[23] Arnsten AF. Catecholamine regulation of the prefrontal cortex. J Psychopharmacol, 1997, 11(2): 151-162.  doi: 10.1177/026988119701100208
[24] Granon S, Passetti F, Thomas KL, et al. Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. J Neurosci, 2000, 20(3): 1208-1215.  doi: 10.1523/JNEUROSCI.20-03-01208.2000